東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Treatment of cystic fibrosis and oth...

Azuma, Arata.

FindBook

Google Book

Amazon

博客來

Treatment of cystic fibrosis and other rare lung diseases

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Treatment of cystic fibrosis and other rare lung diseases/ edited by Arata Azuma, Michael S. Schechter.
其他作者:	Azuma, Arata.
出版者:	Basel :Springer Basel : : 2017.,
面頁冊數:	viii, 263 p. :ill., digital ;24 cm.
內容註:	Part I Etiopathology and Genetics of Rare Lung Diseases -- Part II Treatment of Cystic Fibrosis -- Part III Treatment of Other Rare Lung Diseases.
Contained By:	Springer eBooks
標題:	Cystic fibrosis - Treatment. -
電子資源:	http://dx.doi.org/10.1007/978-3-0348-0977-1
ISBN:	9783034809771

Treatment of cystic fibrosis and other rare lung diseases
Treatment of cystic fibrosis and other rare lung diseases[electronic resource] /edited by Arata Azuma, Michael S. Schechter. - Basel :Springer Basel :2017. - viii, 263 p. :ill., digital ;24 cm. - Milestones in drug therapy,2296-6056. - Milestones in drug therapy..

Part I Etiopathology and Genetics of Rare Lung Diseases -- Part II Treatment of Cystic Fibrosis -- Part III Treatment of Other Rare Lung Diseases.

This volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions. It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.

ISBN: 9783034809771

Standard No.: 10.1007/978-3-0348-0977-1doiSubjects--Topical Terms:

2163092
Cystic fibrosis
--Treatment.

LC Class. No.: RC858.C95

Dewey Class. No.: 616.372

Treatment of cystic fibrosis and other rare lung diseases
LDR:02199nmm a2200325 a 4500 001 2089976
003 DE-He213
005 20170201181627.0
006 m d
007 cr nn 008maaau
008 171013s2017 sz s 0 eng d
020 $a 9783034809771 $q (electronic bk.)
020 $a 9783034809757 $q (paper)
024 7 $a 10.1007/978-3-0348-0977-1 $2 doi
035 $a 978-3-0348-0977-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC858.C95
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 616.372 $2 23
090 $a RC858.C95 $b T784 2017
245 0 0 $a Treatment of cystic fibrosis and other rare lung diseases $h [electronic resource] / $c edited by Arata Azuma, Michael S. Schechter.
260 $a Basel : $b Springer Basel : $b Imprint: Springer, $c 2017.
300 $a viii, 263 p. : $b ill., digital ; $c 24 cm.
490 1 $a Milestones in drug therapy, $x 2296-6056
505 0 $a Part I Etiopathology and Genetics of Rare Lung Diseases -- Part II Treatment of Cystic Fibrosis -- Part III Treatment of Other Rare Lung Diseases.
520 $a This volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions. It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.
650 0 $a Cystic fibrosis $x Treatment. $3 2163092
650 0 $a Lungs $x Diseases $x Treatment. $3 1244748
650 1 4 $a Biomedicine. $3 890831
650 2 4 $a Pharmacology/Toxicology. $3 890953
650 2 4 $a Pneumology/Respiratory System. $3 894348
650 2 4 $a Internal Medicine. $3 858559
650 2 4 $a Immunology. $3 611031
700 1 $a Azuma, Arata. $3 3221084
700 1 $a Schechter, Michael S. $3 3221085
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Milestones in drug therapy. $3 1565346
856 4 0 $u http://dx.doi.org/10.1007/978-3-0348-0977-1
950 $a Biomedical and Life Sciences (Springer-11642)